迈达普

迈达普

软件开发

Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research

关于我们

Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research. Huma’s technology has powered over 3,000 hospitals and clinics, with 500+ unique deployments across 70+ countries. The software has been used to engage and screen over 35 million individuals, with 1.8 million active users across its various products. The company is renowned for its role in major national healthcare projects worldwide, from the US and the UK to Germany, Greece, and Saudi Arabia, as well as working with most large pharma companies and CROs. The Huma Cloud Platform offers a technology infrastructure built on strong regulatory foundations to launch digital solutions for healthcare and research. Huma has achieved FDA 510(k) Class II, EU/MDR Class IIb, and Saudi FDA Class C regulatory clearance for its disease-agnostic flagship product, enabling rapid, code-free configuration with the ability to host AI/ML models.

网站
https://www.huma.com
所属行业
软件开发
规模
501-1,000 人
总部
London
类型
私人持股
创立
2011
领域
Digital clinical trials、Remote patient monitoring和Digital companion apps

地点

迈达普员工

动态

  • 查看迈达普的公司主页,图片

    33,329 位关注者

    ?? The three most common challenges in clinical trials and their solutions: Discover a new white paper written by our in-house CRO on overcoming key challenges in clinical trials. We showcase innovative, technological and patient-centric solutions to prevent costly delays caused by recurring hurdles. Download on the link below! https://lnkd.in/dV2nWRcC

    • 该图片无替代文字
  • 查看迈达普的公司主页,图片

    33,329 位关注者

    ?? Exciting CNS Summit news! ?? We are thrilled to announce that Dan Vahdat, our CEO, and Dr Mert Aral, our CMO, will take the stage for two pivotal sessions this year. ?? Spotlight Session: Build and Deploy Medical Apps (with FDA 510k) or Research Apps in Hours Instead of Years ?? Date: Monday, November 11th ?? Session Time: 1:00 – 1:50 PM ET ?? Location: Renoir 1/2 Get ready for something special! Dan and Mert will co-present a live demo, showcasing a transformative platform that drastically cuts development time from years to hours. Our breakthrough technology enables rapid deployment and iteration of digital health applications for clinical trials, remote monitoring, and companion SaMD—all while ensuring regulatory compliance across global markets. ?? Panel Session: Digital Medicine Forum: Dan Vahdat (Huma) and Edward Cox (Pfizer), Moderated by Ritesh Patel (FINN Partners) ?? Date: Wednesday, November 13th ?? Session Time: 11:00 AM – 12:00 PM ET ?? Location: Picasso Ballroom In this panel, Dan and Ed will discuss how creating digital tools for patient engagement, data collection, and monitoring in clinical trials must be flexible, cost-efficient, and fast—because delays aren’t an option. They will discuss our work to utilise digital health to reduce development time from years to hours, enabling quick launches and rapid iteration of trial software. They’ll also discuss how this aligns with the latest FDA guidance on Prescription Drug Use-Related Software (PDURS), driving faster trials, cost savings, and streamlined project execution. If you’re attending the CNS Summit, don’t miss these sessions! We can’t wait to share how our innovations are shaping the future of digital health and clinical research. #CNSSummit #DigitalHealth #ClinicalTrials #PatientEngagement #RegulatoryCompliance #HumaInnovation #CNSSummit2024

    • 该图片无替代文字
  • 查看迈达普的公司主页,图片

    33,329 位关注者

    ?? Big ambitions, bold vision! Our CEO and founder, Dan Vahdat, recently joined The Venture Podcast with McKinsey & Company’s Timothy Yap, Senior Partner, to share the incredible journey behind Huma’s mission to reshape healthcare. ?? Growing up in a family of doctors, Dan saw firsthand how patient care often fades once they leave the hospital—leading to preventable complications. Driven by this, Dan founded Huma in 2011 with one clear purpose: to make healthcare proactive. But back then, the technology was just a dream. ??Fast forward to today, and Huma’s AI-powered Cloud Platform, combined with wearable tech, is making that dream a reality. "We’re now at a point where real-time data can drive real-time interventions," Dan says. With regulatory approval in the US and EU, Huma’s platform is not only enabling proactive patient care but empowering other health tech companies to build on our foundation. ??Dan’s vision? To build the world’s largest digital health company—one that redefines care across the globe, bringing everyone to a world of seamless, continuous healthcare. Catch Dan’s conversation with McKinsey’s Timothy Yap on The Venture Podcast and join us as we shape the future of healthcare! https://lnkd.in/d9jPqrSH

    Harnessing AI to revolutionize healthcare: A conversation with Huma’s Dan Vahdat

    Harnessing AI to revolutionize healthcare: A conversation with Huma’s Dan Vahdat

    omny.fm

  • 查看迈达普的公司主页,图片

    33,329 位关注者

    Huma intelligence (Hi) update: We’ve developed a model at Huma called Trans-ROM to accurately measure range-of-motion across various exercises. The Trans-ROM algorithm can deliver reliable, real-time, actionable insights for rehabilitation, physical therapy, or sports performance directly from an individual's mobile device. Our model excels in even the most challenging conditions, including when users are positioned on their side, ensuring precision in detecting occluded joints. The model has been technically validated as part of a Gait lab study. Want to explore more about this cutting-edge technology and its potential applications for your work? Reach out! #Huma #AI #MachineLearning #RangeOfMotion #HealthcareInnovation #PhysicalTherapy #Rehabilitation

  • 查看迈达普的公司主页,图片

    33,329 位关注者

    Huma CEO & Founder Dan Vahdat joined Tom Mackenzie of Bloomberg to share how we are accelerating the adoption of digital/AI across care and research through the Huma Cloud Platform, as well as acquisitions like eConsult, with the goal of building an end-to-end, digital-first care offering. Click below to learn more about our strategy behind the acquisition and our plans for the future: https://lnkd.in/e_nrWstB

    • 该图片无替代文字
  • 查看迈达普的公司主页,图片

    33,329 位关注者

    A Huma-powered Bayer program has broken a #GuinnessWorldRecord! ?? In support of Aspirin, and in combination with other initiatives, our technology has powered the highest number of cardiovascular disease (CVD) screenings ever done in 12 hours as part of #WorldHeartDay. We are immensely proud to support the Bayer team in their mission to save millions of lives?by breaking down barriers and enhancing accessibility, awareness, and diagnosis of CVD. Guinness World Records #CardiovascularDisease #DigitalHealth

    • 该图片无替代文字
  • 查看迈达普的公司主页,图片

    33,329 位关注者

    Mark your calendars for September 25! Join us for an exclusive webinar where industry experts from Alcedis - a HUMA company, AstraZeneca, and CompuGroup Medical SE & Co. KGaA will share groundbreaking insights from the?innovative InspeCKD study. The InspeCKD study analyzed over?400,000 anonymized patient records?from?1,250 general practices?across Germany to uncover important trends in?chronic kidney disease (CKD)?screening and diagnostics. Learn about the cutting-edge methods used, how real-world data was leveraged, and the strategies developed to overcome the challenges of data integration. Don’t miss this opportunity to gain valuable insights from leaders in the field and stay ahead of the curve. Our speakers: Dr. Nils Kost?- Director Evidence at?AstraZeneca Philipp Thiele?- General Manager of?CompuGroup Medical SE & Co. KGaA Frederik M. Mader?- Specialist in general medicine and Professor at IU International University Dr. Hendrik Melior?- Project Manager Clinical Operations at Alcedis Register here: https://lnkd.in/eCjnSb4y Read more about InspeCKD: https://lnkd.in/eH_5haQV

    • 该图片无替代文字
  • 查看迈达普的公司主页,图片

    33,329 位关注者

    At Huma, we believe that AI is key to enabling personalised care at scale. Our HumaMG program uses advanced machine learning and imaging capabilities to support improved monitoring of disease progression for people with #MyastheniaGravis. On September 26, Huma's Chief Medical Officer Dr Mert Aral and Benjamin Irving, VP ML & Imaging, will be leading a webinar session hosted by the Myasthenia Gravis Foundation of America, Inc., in which they'll share more on the HumaMG app and how it uses AI to enhance the #MG care pathway. Living Better with MG: How AI Enhances Treatment and Management ?? Date: Thursday, September 26, 12pm EST ?? Register here:https://lnkd.in/efa96_nJ ?? Learn more about HumaMG: https://lnkd.in/eekJTUxQ

    • 该图片无替代文字

相似主页

查看职位

融资

迈达普 共 11 轮

上一轮

D 轮

US$80,000,000.00

Crunchbase 上查看更多信息